Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Waterloo man found guilty for fentanyl distribution, money laundering
Javoni Marcelius Butler, 43, convicted of fentanyl distribution and money laundering, faces 5-100 years in prison.
Darzalex-based quadruplet regimen receives positive CHMP opinion for transplant-eligible
Janssen-Cilag International NV announces CHMP recommendation for DARZALEX subcutaneous formulation in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients eligible for autologous stem-cell transplant. Supported by Phase 3 PERSEUS study data, this aims to establish a new standard of care, enhancing progression-free survival.
Type 1 Diabetes (T1D) Market Research Report 2032
The global Type 1 Diabetes (T1D) market, valued at $6.5 billion in 2023, is projected to grow to $11.3 billion by 2032, driven by increasing diabetes prevalence, technological advancements, and rising healthcare expenditure. Innovations like CGM systems and artificial pancreas devices enhance patient outcomes. Insulin therapy remains central, with advancements in delivery methods and digital health integration. Regional growth is led by North America, with Asia Pacific showing rapid expansion. Challenges include treatment costs and access, with efforts underway to improve affordability and equity.
Personalized Precision Medicine Market Share | 2031 Forecast
The global Personalized Precision Medicine Market report offers detailed segmentation and strategic guidance, covering manufacturers, regions, product categories, and applications. Key insights include market evolution, current conditions, future projections, and analysis of key players like Agilent Technologies, Biogen, Johnson & Johnson, and Novartis. The report aids stakeholders in navigating market dynamics and capitalizing on opportunities.
US FDA approves J&J's Rybrevant plus standard of care as first and only targeted regimen
FDA approves Rybrevant (amivantamab-vmjw) plus chemotherapy for EGFR-mutated NSCLC, showing improved progression-free survival and response rates in MARIPOSA-2 study.
FDA Approves Rybrevant for Locally Advanced, Metastatic Epidermal Growth Factor
FDA approves J&J's Rybrevant with chemotherapy for EGFR-mutated NSCLC, reducing disease progression risk by 52%. Combination therapy showed median PFS of 6.3 months vs. 4.2 months with solo chemotherapy, and overall response rate of 53% vs. 29%. Common AEs included rash, infusion-related reactions, and fatigue.
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of ...
FDA approves Johnson & Johnson's Rybrevant in combination with chemotherapy for locally advanced or metastatic NSCLC with EGFR exon 19 deletions or L858R mutations, marking its third approval in 2024.
After July surge, FDA approvals for GI settle into summer lull: What you may have missed
After a July surge in FDA approvals for gastroenterology, including the first blood test for colorectal cancer, the agency saw a summer lull with only three GI approvals. Notable approvals included Skyrizi for UC and Crohn’s, a rapid HCV test for point-of-care use, and a third ustekinumab biosimilar.
FDA Approves Amivantamab for EGFR-Positive NSCLC With Exon 19 Deletion, Exon 21
FDA approves amivantamab-vmjw (Rybrevant) with chemotherapy for EGFR-mutated NSCLC progressing after EGFR TKI treatment. This combination is the only NCCN category 1 option for patients with multiple lesions after osimertinib failure. Phase 3 MARIPOSA-2 study showed improved progression-free survival and overall response rates compared to chemotherapy alone.
Related Clinical Trials:
FDA Approval Makes a Zevra Drug the First Therapy for Rare and Fatal Metabolic Disease
Zevra Therapeutics' drug, Miplyffa (acrimoclomol), is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), a fatal inherited metabolic disorder. The drug, taken three times daily, aims to slow NPC's progression, with FDA approval specifically for neurological effects. Miplyffa should be used with miglustat, and common side effects include upper respiratory tract infection, diarrhea, and weight loss. Zevra expects the drug to be available in the U.S. within 8-12 weeks.
© Copyright 2025. All Rights Reserved by MedPath